CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

ABSTRACT: Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective. CYP2C19 is encoded by a polymorphic gene; variants in the CYP2C19 gene, which vary in frequency in different ethnic groups can abolish, reduce or increase enzyme activity, thereby affecting the conversion of clopidogrel to its active metabolite. Individuals who have either one or two loss-of-function alleles are referred to as intermediate and poor metabolisers, respectively, and in these patients, the clinical effectiveness of clopidogrel is reduced or absent. Any patient

SUBMITTER: Dello Russo C 

PROVIDER: S-EPMC12850553 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature